Detalhe da pesquisa
1.
Unveiling Treatment Response Predictors in Predominant Subtypes of Chronic Inducible Urticaria.
Int Arch Allergy Immunol
; : 1-11, 2024 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38889696
2.
Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: Clinical features, associated conditions and indicators of treatment response.
Pediatr Allergy Immunol
; 34(2): e13925, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36825740
3.
Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria.
Asian Pac J Allergy Immunol
; 2021 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33638627
4.
Fric Test Revisited: A Suggestion for a New Scoring System and Its Correlation with Urticaria Control Test and Dermatology Life Quality Index.
Int Arch Allergy Immunol
; 178(1): 76-82, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30286461
5.
Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
An Bras Dermatol
; 97(5): 592-600, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35853771
6.
Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema.
World Allergy Organ J
; 14(7): 100554, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34221217
7.
Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
J Dermatol Sci
; 87(1): 60-69, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28314658
8.
Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
An. bras. dermatol
; 97(5): 592-600, Sept.-Oct. 2022. tab, graf
Artigo
em Inglês
|
LILACS-Express
| ID: biblio-1403153